Morphic (MORF)
(Delayed Data from NSDQ)
$56.82 USD
+0.16 (0.28%)
Updated Aug 1, 2024 04:00 PM ET
After-Market: $56.84 +0.02 (0.04%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
MORF 56.82 +0.16(0.28%)
Will MORF be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for MORF based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MORF
Pharma Stock Roundup: LLY to Buy Morphic, PFE Advances Obesity Drug Development
Eli Lilly (LLY) to Buy Morphic for $3.2B, Boost IBD Presence
MORF: What are Zacks experts saying now?
Zacks Private Portfolio Services
Company News for July 9, 2024
What Makes Morphic (MORF) a New Buy Stock
Wall Street Analysts See a 56.18% Upside in Morphic Holding, Inc. (MORF): Can the Stock Really Move This High?
Other News for MORF
Morphic Holding ticks higher after HSR waiting period for Eli Lilly deal expires
MORF Alert: Wohl & Fruchter LLP Files Class Action Lawsuit on Behalf of Shareholders of Morphic Holding, Inc., in the U.S. District Court for the Northern District of California
Analysts Have Conflicting Sentiments on These Healthcare Companies: Morphic Holding (MORF), Pyxis Oncology (PYXS) and Zynex (ZYXI)
Morphic Holding (MORF) Receives a Hold from RBC Capital
MORF Stock Earnings: Morphic Holding Misses EPS for Q2 2024